These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 38684670)
1. The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression. Medina-Herrera A; Vazquez I; Cuenca I; Rosa-Rosa JM; Ariceta B; Jimenez C; Fernandez-Mercado M; Larrayoz MJ; Gutierrez NC; Fernandez-Guijarro M; Gonzalez-Calle V; Rodriguez-Otero P; Oriol A; Rosiñol L; Alegre A; Escalante F; De La Rubia J; Teruel AI; De Arriba F; Hernandez MT; Lopez-Jimenez J; Ocio EM; Puig N; Paiva B; Lahuerta JJ; Bladé J; San Miguel JF; Mateos MV; Martinez-Lopez J; Calasanz MJ; Garcia-Sanz R; Blood Cancer J; 2024 Apr; 14(1):74. PubMed ID: 38684670 [TBL] [Abstract][Full Text] [Related]
2. Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression. Bustoros M; Sklavenitis-Pistofidis R; Park J; Redd R; Zhitomirsky B; Dunford AJ; Salem K; Tai YT; Anand S; Mouhieddine TH; Chavda SJ; Boehner C; Elagina L; Neuse CJ; Cha J; Rahmat M; Taylor-Weiner A; Van Allen E; Kumar S; Kastritis E; Leshchiner I; Morgan EA; Laubach J; Casneuf T; Richardson P; Munshi NC; Anderson KC; Trippa L; Aguet F; Stewart C; Dimopoulos MA; Yong K; Bergsagel PL; Manier S; Getz G; Ghobrial IM J Clin Oncol; 2020 Jul; 38(21):2380-2389. PubMed ID: 32442065 [TBL] [Abstract][Full Text] [Related]
3. Gene Expression Analysis of the Bone Marrow Microenvironment Reveals Distinct Immunotypes in Smoldering Multiple Myeloma Associated to Progression to Symptomatic Disease. Isola I; Brasó-Maristany F; Moreno DF; Mena MP; Oliver-Calders A; Paré L; Rodríguez-Lobato LG; Martin-Antonio B; Cibeira MT; Bladé J; Rosiñol L; Prat A; Lozano E; Fernández de Larrea C Front Immunol; 2021; 12():792609. PubMed ID: 34880879 [TBL] [Abstract][Full Text] [Related]
4. Three-dimensional telomere profiling predicts risk of progression in smoldering multiple myeloma. Kumar S; Rajkumar SV; Jevremovic D; Kyle RA; Shifrin Y; Nguyen M; Husain Z; Alikhah A; Jafari A; Mai S; Anderson K; Louis S Am J Hematol; 2024 Aug; 99(8):1532-1539. PubMed ID: 38747543 [TBL] [Abstract][Full Text] [Related]
5. Genomic Profiling to Contextualize the Results of Intervention for Smoldering Multiple Myeloma. Kazandjian D; Diamond B; Papadimitriou M; Hill E; Sklavenitis-Pistofidis R; Ziccheddu B; Blaney P; Chojnacka M; Durante M; Maclachlan K; Young R; Usmani S; Davies F; Getz G; Ghobrial I; Korde N; Morgan G; Maura F; Landgren O Clin Cancer Res; 2024 Oct; 30(19):4482-4490. PubMed ID: 38652812 [TBL] [Abstract][Full Text] [Related]
7. The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma. Boyle EM; Deshpande S; Tytarenko R; Ashby C; Wang Y; Bauer MA; Johnson SK; Wardell CP; Thanendrarajan S; Zangari M; Facon T; Dumontet C; Barlogie B; Arbini A; Rustad EH; Maura F; Landgren O; Zhan F; van Rhee F; Schinke C; Davies FE; Morgan GJ; Walker BA Nat Commun; 2021 Jan; 12(1):293. PubMed ID: 33436579 [TBL] [Abstract][Full Text] [Related]
8. The Role of Early Intervention in High-Risk Smoldering Myeloma. Joseph NS; Dhodapkar MV; Lonial S Am Soc Clin Oncol Educ Book; 2020 Mar; 40():1-9. PubMed ID: 32182141 [TBL] [Abstract][Full Text] [Related]
9. Therapeutic Advances in the Management of Smoldering Myeloma. Khan R; Zahid U; Kollu V; Jahan N; Ali M; Tricot G; Anwer F Am J Ther; 2020; 27(2):e194-e203. PubMed ID: 31842112 [TBL] [Abstract][Full Text] [Related]
10. Prognostic value of involved/uninvolved free light chain ratio determined by Freelite and N Latex FLC assays for identification of high-risk smoldering myeloma patients. Henriot B; Rouger E; Rousseau C; Escoffre M; Sébillot M; Bendavid C; Minvielle S; Avet-Loiseau H; Decaux O; Moreau C Clin Chem Lab Med; 2019 Aug; 57(9):1397-1405. PubMed ID: 30973821 [TBL] [Abstract][Full Text] [Related]
11. Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma. Korde N; Roschewski M; Zingone A; Kwok M; Manasanch EE; Bhutani M; Tageja N; Kazandjian D; Mailankody S; Wu P; Morrison C; Costello R; Zhang Y; Burton D; Mulquin M; Zuchlinski D; Lamping L; Carpenter A; Wall Y; Carter G; Cunningham SC; Gounden V; Sissung TM; Peer C; Maric I; Calvo KR; Braylan R; Yuan C; Stetler-Stevenson M; Arthur DC; Kong KA; Weng L; Faham M; Lindenberg L; Kurdziel K; Choyke P; Steinberg SM; Figg W; Landgren O JAMA Oncol; 2015 Sep; 1(6):746-54. PubMed ID: 26181891 [TBL] [Abstract][Full Text] [Related]
12. International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM). Mateos MV; Kumar S; Dimopoulos MA; González-Calle V; Kastritis E; Hajek R; De Larrea CF; Morgan GJ; Merlini G; Goldschmidt H; Geraldes C; Gozzetti A; Kyriakou C; Garderet L; Hansson M; Zamagni E; Fantl D; Leleu X; Kim BS; Esteves G; Ludwig H; Usmani S; Min CK; Qi M; Ukropec J; Weiss BM; Rajkumar SV; Durie BGM; San-Miguel J Blood Cancer J; 2020 Oct; 10(10):102. PubMed ID: 33067414 [TBL] [Abstract][Full Text] [Related]
13. Advances in the management of asymptomatic myeloma. Mateos MV Curr Opin Oncol; 2014 Nov; 26(6):670-6. PubMed ID: 25210868 [TBL] [Abstract][Full Text] [Related]
14. Progress in the Management of Smoldering Multiple Myeloma. Schmidt TM; Callander NS Curr Hematol Malig Rep; 2021 Apr; 16(2):172-182. PubMed ID: 33983517 [TBL] [Abstract][Full Text] [Related]
16. [Significant changes in diagnostic and therapeutic procedures in smoldering multiple myeloma]. Jurczyszyn A; Olszewska-Szopa M; Skotnicki AB Przegl Lek; 2015; 72(11):642-8. PubMed ID: 27012123 [TBL] [Abstract][Full Text] [Related]
17. Smoldering multiple myeloma: the role of different scoring systems in identifying high-risk patients in real-life practice. Cocito F; Mangiacavalli S; Ferretti VV; Cartia CS; Ganzetti M; Benveuti P; Pompa A; Catalano M; Fugazza E; Landini B; Arcaini L; Corso A Leuk Lymphoma; 2019 Dec; 60(12):2968-2974. PubMed ID: 31169049 [TBL] [Abstract][Full Text] [Related]
18. [Correlation between Morphological Typing and Monoclonality of Bone Marrow Plasma Cells and Its Diagnostic Value for High-Risk Smoldering Multiple Myeloma]. Xiao HJ; Wang QJ; Wu S; Dai XB; Zhuang YP Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Aug; 32(4):1146-1151. PubMed ID: 39192411 [TBL] [Abstract][Full Text] [Related]
20. 2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde. Musto P; Engelhardt M; Caers J; Bolli N; Kaiser M; Van de Donk N; Terpos E; Broijl A; De Larrea CF; Gay F; Goldschmidt H; Hajek R; Vangsted AJ; Zamagni E; Zweegman S; Cavo M; Dimopoulos M; Einsele H; Ludwig H; Barosi G; Boccadoro M; Mateos MV; Sonneveld P; Miguel JS Haematologica; 2021 Nov; 106(11):2799-2812. PubMed ID: 34261295 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]